Thank you, Jeffrey, and good afternoon, everyone. Please turn to Slide seven. Revenue in the quarter of $704 million was up 7% year over year, and toward the higher end of our prior guidance. Our non-GAAP EPS was $0.71, which exceeded our prior guidance of $0.62 to $0.68. As a reminder, our non-GAAP results exclude stock-based compensation, amortization of intangible assets, restructuring, impairment, and other items as noted in appendix one of this presentation. For Q4, our non-GAAP gross margin was 10.6%, up 50 basis points sequentially and 20 basis points year over year due to volume and mix. Non-GAAP operating margin of 5.5% was up 70 basis points sequentially and 40 basis points year over year, driven by our ability to leverage our cost basis on higher revenue. Our fourth quarter non-GAAP effective tax rate was 25.4%. Please turn to slide eight for the full year 2025 financial results. For the fiscal year, revenue of $2.66 billion was flat compared to the prior year, while non-GAAP EPS was up 5% to $2.40. For the full year, our non-GAAP gross margin was 10.2%, and non-GAAP operating margin of 4.9% was down 20 basis points year over year, primarily due to variable compensation. Our full-year non-GAAP effective tax rate was 24.8%. Please turn to slides nine and ten for our fourth quarter and full-year 2025 revenue performance by sector. Semi cap revenue decreased 8% quarter over quarter and 14% year over year. This was consistent with our expectations of a softer Q4 prior to expected improvements in 2026. For the full year, semi cap revenue grew 2%. Within industrial, although down sequentially, revenue was up 3% year over year. This was in line with our expectations for the quarter. For the full year, industrial revenue was consistent with the prior year. A and D posted another strong performance in the quarter and year, up 7% sequentially and 17% year over year. Full-year revenue growth was also well into the double digits at 19%. Meanwhile, medical continued to improve with fourth-quarter revenue up 14% quarter over quarter and 23% compared to the prior year. The improved second-half performance drove 7% growth on a full-year basis. For our final sector, full-year AC and C revenue was down in 2025, driven by a challenging first half. However, we are pleased with the return to growth in the fourth quarter with revenue up 22% sequentially and 27% year over year. We expect this momentum to continue into Q1 as we ramp previously announced AI-related wins. Please turn to slide 11 for trended non-GAAP financials. Our Q4 revenue continued the sequential improvements that we saw throughout the year, exiting at a little over $700 million, which was up 7% versus Q4 2024. At the same time, fourth-quarter gross margin of 10.6% continued our multi-quarter trend of 10% or greater performance. Coupled with expense management, this translated into sequential improvements in operating margin and EPS performance throughout the year, with fourth-quarter and full-year EPS growing greater than twice the rate of revenue growth. Please refer to slides twelve and thirteen for discussion of our balance sheet, cash flow, and working capital trends. In Q4, we generated $59 million in operating cash flow, and $48 million in free cash flow. For fiscal year 2025, we generated $85 million in free cash flow. As of December 31, we are in a net cash positive position of $111 million. Our cash balance was $322 million, a sequential increase of $36 million. As of December 31, we had $148 million outstanding on our term loan and $65 million outstanding against our revolver, from which we have $481 million available to borrow. We invested approximately $39 million in capital expenditures during the year, including $11 million in Q4. Which will require a step up in capital spending over the next few quarters. Our fourth building in Penang is expected to be completed in Q2 and begin operations in Q3. Demonstrating our ongoing commitment to return, we distributed cash dividends of $24 million and repurchased $27 million in stock during the year. At the end of the quarter, we had $123 million remaining under our existing share repurchase authorization. Our cash conversion cycle in the quarter was sixty-seven days as our working capital focus drove considerable improvements of ten days sequentially and twenty-two days year over year. Inventory days were down six days sequentially as we continued to actively manage our inventory as we grew the top line. This focus translated into inventory turns of 5.2 in the quarter. Before discussing our Q1 guidance, there are two things that I want to highlight. First, during our year-end close process, we identified and corrected immaterial errors in prior periods related to our tax calculation resulting in a cumulative understatement of income tax expense of $8.7 million. The aggregate impact of these corrections was an increase to income tax expense of $2.2 million for the fiscal year ended 12/31/2024, and an increase of income tax expense of $6.5 million two years prior to 2024. Importantly, these corrections resulted in no change to previously reported cash taxes, operating cash flow, revenue, gross and operating margin, or non-GAAP earnings per share. Consistent with GAAP guidance, prior year periods in today's release have been revised accordingly, which will also be reflected in our Form 10-K set to be published the week of February 23. Second, as we look to optimize our footprint, we recorded an $11.1 million noncash impairment on certain assets located at one of our Arizona facilities due to the end of life of a few programs. Any follow-on programs will be consolidated within our other US facilities. Please advance to slide 14. Let me now turn to our guidance for 2026. We expect revenue to be within a range of $655 to $695 million, up 7% year over year at the midpoint. We expect non-GAAP gross margin to be between 10.4% and 10.6%. With those assumptions, we would expect non-GAAP operating margin to be between 4.7% and 4.9%. We anticipate GAAP expenses to include approximately $5.4 million of stock-based compensation and $5.1 to $5.5 million of non-operating expenses including amortization, restructuring, and other charges. Our non-GAAP diluted earnings per share is expected to be in the range of $0.53 to $0.59. Interest and other expenses are expected to be approximately $4.7 million. We are undertaking initiatives aimed at structurally improving our tax rate over the long term. However, for the first quarter and full year, we anticipate that our effective tax rate will be in the range of 26% to 27%. Finally, our weighted average share count is expected to be approximately 36.3 million. With that, I would like to turn the call over to David to discuss market sector performance and outlook. David?